Serretta V, Lo Presti D, Vasile P, Gange E, Esposito E, Menozzi I
Department of Urology, Civic Hospital, Palermo, Italy.
Urology. 1998 Nov;52(5):793-6. doi: 10.1016/s0090-4295(98)00332-x.
To evaluate the nuclear matrix protein 22 (NMP22) test in the management of patients after transurethral resection (TUR) of recurrent transitional cell carcinoma of the bladder.
The NMP22 test was performed in 137 patients: in 42 patients, a bladder recurrence was detected by cystoscopy and histologically confirmed; 95 patients were recurrence-free at cytology and cystoscopy performed at least 3 months after TUR.
In patients with tumoral recurrence, the mean NMP22 value was 54.8 U/mL. The false-negative rate was 28.5%. In recurrence-free patients, the mean NMP22 value was 22.8 U/mL. The specificity of the NMP22 test was 61%. Higher NMP22 mean values (29.6 versus 15.8 U/mL) were found in patients who underwent intravesical chemotherapy or immunotherapy.
Despite its good sensitivity, the NMP22 test cannot be adopted as a routine tool in the surveillance after TUR of patients with superficial bladder cancer because of its low specificity.
评估核基质蛋白22（NMP22）检测在复发性膀胱移行细胞癌经尿道切除（TUR）术后患者管理中的作用。
对137例患者进行了NMP22检测：其中42例患者经膀胱镜检查发现膀胱复发并经组织学证实；95例患者在TUR术后至少3个月进行的细胞学和膀胱镜检查中未发现复发。
肿瘤复发患者的NMP22平均 值为54.8 U/mL。假阴性率为28.5%。未复发患者的NMP22平均值为22.8 U/mL。NMP22检测的特异性为61%。接受膀胱内化疗或免疫治疗的患者NMP22平均值较高（29.6对15.8 U/mL）。
尽管NMP22检测具有良好的敏感性，但由于其特异性较低，不能作为浅表性膀胱癌患者TUR术后监测的常规工具。
